Comparison tool
Compare peptides
Pick up to three compounds. Useful for deciding whether two peptides in a stack actually do different things, or whether you're paying twice for the same pathway.
Select up to three (1/3)
| Attribute | |
|---|---|
| Category | Metabolic |
| Evidence grade | Strong |
| Also known as | LY3437943, Triple G |
| Mechanism | Simultaneously activates GLP-1, GIP and glucagon receptors in a single peptide. The glucagon component increases energy expenditure and hepatic lipid oxidation, while GLP-1 and GIP suppress appetite, slow gastric emptying and improve glucose-dependent insulin secretion. |
| Key benefits | Up to ~24% mean weight loss at 12 mg over 48 weeks in phase 2 · Large reductions in HbA1c and liver fat · Improvements in blood pressure, triglycerides and LDL cholesterol |
| Side effects | Nausea and vomiting · Diarrhoea · Gallbladder issues · Mild resting heart-rate increase · Injection-site reaction |
| Half-life | About 5–7 days |
| Administration | Once-weekly subcutaneous injection |
| Dosing overview | Phase 2 started at 2 mg weekly and escalated to 12 mg over several weeks |
| Storage | Investigational product; typically refrigerated as lyophilised or pen formulation |
| Legal status | Investigational drug; not FDA-approved as of 2026. |
Dosing figures reflect published literature and commonly reported community protocols. They are informational only.